BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38342782)

  • 1. Artificial intelligence for assessment of vascular involvement and tumor resectability on CT in patients with pancreatic cancer.
    Bereska JI; Janssen BV; Nio CY; Kop MPM; Kazemier G; Busch OR; Struik F; Marquering HA; Stoker J; Besselink MG; Verpalen IM;
    Eur Radiol Exp; 2024 Feb; 8(1):18. PubMed ID: 38342782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular involvement and resectability of pancreatic ductal adenocarcinoma on contrast-enhanced MRI: comparison with pancreatic protocol CT.
    Noda Y; Kawai N; Kaga T; Ishihara T; Hyodo F; Kato H; Kambadakone AR; Matsuo M
    Abdom Radiol (NY); 2022 Aug; 47(8):2835-2844. PubMed ID: 35760922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
    Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
    Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.
    Wittel UA; Lubgan D; Ghadimi M; Belyaev O; Uhl W; Bechstein WO; Grützmann R; Hohenberger WM; Schmid A; Jacobasch L; Croner RS; Reinacher-Schick A; Hopt UT; Pirkl A; Oettle H; Fietkau R; Golcher H
    BMC Cancer; 2019 Oct; 19(1):979. PubMed ID: 31640628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of Dark-Blood Dual-Energy CT Images for Predicting Vascular Involvement and R0 Resection in Patients With Pancreatic Cancer.
    Si K; Wu H; Yang M; Guo Y; Zhang X; Ding C; Xue J; Han P; Li X
    AJR Am J Roentgenol; 2023 Jun; 220(6):838-848. PubMed ID: 36541594
    [No Abstract]   [Full Text] [Related]  

  • 6. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applicability of current NCCN Guidelines for pancreatic adenocarcinoma resectability: analysis and pitfalls.
    Garces-Descovich A; Beker K; Jaramillo-Cardoso A; James Moser A; Mortele KJ
    Abdom Radiol (NY); 2018 Feb; 43(2):314-322. PubMed ID: 29392370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artificial intelligence to predict T4 stage of pancreatic ductal adenocarcinoma using CT imaging.
    Miao Q; Wang X; Cui J; Zheng H; Xie Y; Zhu K; Chai R; Jiang Y; Feng D; Zhang X; Shi F; Tan X; Fan G; Liang K
    Comput Biol Med; 2024 Mar; 171():108125. PubMed ID: 38340439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey.
    Badgery HE; Muhlen-Schulte T; Zalcberg JR; D'souza B; Gerstenmaier JF; Pickett C; Samra J; Croagh D;
    HPB (Oxford); 2023 Nov; 25(11):1393-1401. PubMed ID: 37558564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
    Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
    Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot.
    Pilgrim CHC; Maciejewska A; Ayres N; Ellis S; Goodwin M; Zalcberg JR; Haydon A
    ANZ J Surg; 2022 Oct; 92(10):2565-2570. PubMed ID: 36054233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study.
    Kim HY; Lee YJ; Chang W; Cho J; Park JH; Lee JC; Kim J; Hwang JH; Kim YH
    Eur Radiol; 2022 Jun; 32(6):3799-3807. PubMed ID: 35032213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
    Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis.
    Park S; Jang JK; Byun JH; Kim JH; Lee SS; Kim HJ; Hong SB; Park SH
    Eur Radiol; 2021 May; 31(5):3383-3393. PubMed ID: 33123793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
    Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
    J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting pancreatic ductal adenocarcinoma using artificial intelligence analysis of pre-diagnostic computed tomography images.
    Qureshi TA; Gaddam S; Wachsman AM; Wang L; Azab L; Asadpour V; Chen W; Xie Y; Wu B; Pandol SJ; Li D
    Cancer Biomark; 2022; 33(2):211-217. PubMed ID: 35213359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we rely on contrast-enhanced CT to identify pancreatic ductal adenocarcinoma? A population-based study in sensitivity and factors associated with false negatives.
    LeBlanc M; Kang J; Costa AF
    Eur Radiol; 2023 Nov; 33(11):7656-7664. PubMed ID: 37266655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiomics-based Machine-learning Models Can Detect Pancreatic Cancer on Prediagnostic Computed Tomography Scans at a Substantial Lead Time Before Clinical Diagnosis.
    Mukherjee S; Patra A; Khasawneh H; Korfiatis P; Rajamohan N; Suman G; Majumder S; Panda A; Johnson MP; Larson NB; Wright DE; Kline TL; Fletcher JG; Chari ST; Goenka AH
    Gastroenterology; 2022 Nov; 163(5):1435-1446.e3. PubMed ID: 35788343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
    Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
    Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.